NCT00333255View on ClinicalTrials.gov

Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

March 31, 2006

Conditions
Cataract
Interventions
DRUG

Nepafenac Ophthalmic Suspension, 0.1%

Trial Locations (1)

76134

Lehmann Eye Center, Nacogdoches

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY